Andrew Zelenetz, MD
Enriched profileAttending Physician, Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center · Memorial Sloan Kettering Cancer Center
Andrew Zelenetz is Attending Physician, Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center at Memorial Sloan Kettering Cancer Center. OpenAlex indexes 760 publications with 43,631 citations (h-index 98); ClinicalTrials.gov lists 9 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 16 Oct 2026
Andrew Zelenetz, MD, is Attending Physician, Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center. The public record shows 760 publications with 43,631 citations (h-index 98), centered on Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, CNS Lymphoma Diagnosis and Treatment. It also documents an investigator role on 9 registered clinical trials, industry payments reported by 24 companies, 3 NIH-funded awards (1993–2020).
- Most recent indexed publication: 2026 · Journal of clinical oncology
- Top research focus: Lymphoma Diagnosis and Treatment
- 9 registered trials on ClinicalTrials.gov
- Open Payments reporting from 24 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 37 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 323.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 9 registered studies on ClinicalTrials.gov. The most recent:
- A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma
Sponsor: Memorial Sloan Kettering Cancer Center
- Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
Sponsor: Memorial Sloan Kettering Cancer Center
- Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Sponsor: Memorial Sloan Kettering Cancer Center
Industry payments
Updated 16 Oct 2026
24 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- BeOne Medicines USA, Inc.Program year202511 payments$14,879openpaymentsdata.cms.gov ↗
- Ipsen Biopharmaceuticals, IncProgram year20255 payments$12,866openpaymentsdata.cms.gov ↗
- Genentech USA, Inc.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
82.1%Kinase inhibitor82.1%Brukinsa80%Calquence20%Part D<11 patientsDermatology
17.9%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor17.9%Acyclovir100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 16 Oct 2026
3 NIH research awards on record, funded 1993–2020 per NIH RePORTER. The latest:
- Targeting Acetyltransferase Gene Inactivation in Diffuse Large B Cell Lymphoma
Sloan-Kettering Inst Can Research
FY2020$379,081P50CA192937
Congress activity
Updated 16 Oct 2026
179 congress contributions (2000–2026) across AACR, ASCO, ASH, ASTRO, ESMO per OpenAlex. The most recent:
- Advanced practice provider led programs improve patient access: The APP lymphoma diagnostic program
ASH Annual Meeting
ASH2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in TP53-Mutated Diffuse Large B-Cell Lymphoma.
Journal of clinical oncology
Review2026 - Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study.
Blood advances
Clinical Trial2026 - Consensus recommendations from the 2024 International Follicular Lymphoma Scientific Workshop.
Blood advances
Review2026
Most-cited works
by citation count (OpenAlex)- 01The 2016 revision of the World Health Organization classification of lymphoid neoplasmsArticle7,854 citations2016
- 02Genetics and Pathogenesis of Diffuse Large B-Cell LymphomaArticle2,289 citations2018
- 03Idelalisib and Rituximab in Relapsed Chronic Lymphocytic LeukemiaArticle1,691 citations2014
- 04
- 05
Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/andrew-zelenetz-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/profile/Andrew-Zelenetz-2
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - LinkedIn
linkedin.com/in/andrewzelenetz
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- Other
lymphoma.org/news/foundation-announces-andrew-d-zelenetz-md-phd-as-scientific-advisory-board-chair
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lymphoma.org ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Harvard Medical School
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →prweb.com ↗ - PhD
Harvard University Graduate School of Arts and Sciences, Division of Medical Sciences
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →prweb.com ↗ - BA
Harvard College
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →prweb.com ↗ - Board Certified
Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - Board Certified
Medical Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - Internship and residency in Internal Medicine
Stanford University Medical Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →prweb.com ↗ - Clinical and research fellowship in Oncology
Stanford University Medical Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →prweb.com ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lymphoma.org ↗
- Member
Scientific Advisory Board, Lymphoma Research Foundation
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - Chairperson
Non-Hodgkin Lymphoma Guidelines Panel, National Comprehensive Cancer Network
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - Vice Chairperson
Lymphoma Core Committee, Cancer and Leukemia Group B
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - Editorial Board Member
JNCCN (Journal of the National Comprehensive Cancer Network)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →jnccn.org ↗ - Professor of Medicine
Weill Cornell Medical College
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vivo.weill.cornell.edu ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Secondary affiliations
appointments beyond the home institution- Professor of Medicine
Weill Cornell Medical College
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vivo.weill.cornell.edu ↗
Media & interviews
press, podcasts and appearances- "Zelenetz Discusses How to Evaluate Responses to Therapy in DLBCL" - interview feature
AJMC (The American Journal of Managed Care)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ajmc.com ↗ - Video interview series on lymphoma/CLL topics
VJHemOnc (Video Journal of Hematological Oncology)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vjhemonc.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center
Mark Kris, MD
Memorial Sloan Kettering Cancer Center
Seth Steinberg, PhD
National Cancer Institute (NCI)
Gilles Salles
Memorial Sloan Kettering Cancer Center
Wyndham Wilson, MD
National Cancer Institute (NCI)
Julie Vose, MD
University of Nebraska Medical Center